

Order of Scheduled Presentations

TOPIC: Facet Neurotomy

	Name	Notes
	Paul Dreyfuss, MD EvergreenHealth Sport & Spine Care	
	Alison Stout, DO EvergreenHealth Sport & Spine Care	
1.	Ryan Zehnder, MD EvergreenHealth Sport & Spine Care	No slides.
	Brandon Messerli, DO EvergreenHealth Sport & Spine Care	
	Doug Burns, MD EvergreenHealth Sport & Spine Care	
2.	Kevin VorenKamp, MD EvergreenHealth Sport & Spine Care	

Disclosure

Any unmarked topic will be considered a "Yes"

	Potential Conflict Type	Yes	No
1.	Salary or payments such as consulting fees or honoraria in excess of \$10,000.		7
2.	Equity interests such as stocks, stock options or other ownership interests.		7
3.	Status or position as an officer, board member, trustee, owner.		7
4.	Loan or intellectual property rights.		2
5.	Research funding.		7
6.	Any other relationship, including travel arrangements.		X

If yes, list name of organizations that relationship(s) are with and for #6, describe other relationship:

	Potential Conflict Type	Yes	No
7.	Representation: if representing a person or organization, include the name and funding sources (e.g. member dues, governmental/taxes, commercial products or services, grants from industry or government).		\times

If yes to #7, provide name and funding Sources: _____

If you believe that you do not have a conflict but are concerned that it may appear that you do, you may **attach additional sheets** explaining why you believe that you should not be excluded.

 I certify that I have read and understand this Conflict of Interest Form and that the information I have provided is true, complete, and correct as of this date.

 X
 2,2314
 PAJ Dreybuss

 Signature
 Date
 Print Name

Evergreen Sport &Spine

Washington State Health Care Authority

Feb 25 2014 01:15pm

Health Technology Assessment

P003/003

Disclosure

Any unmarked topic will be considered a "Yes"

	Potential Conflict Type	Yes	No/
1.	Salary or payments such as consulting fees or honoraria in excess of \$10,000.		
2.	Equity interests such as stocks, stock options or other ownership interests.		
3.	Status or position as an officer, board member, trustee, owner.		
4.	Loan or intellectual property rights.		
5.	Research funding.		
6,	Any other relationship, including travel arrangements.		
	· · · · · · · · · · · · · · · · · · ·		V

If yes, list name of organizations that relationship(s) are with and for #6, describe other relationship:

	Potential Conflict Type	Yes	No
7.	Representation: if representing a person or organization, include the name and funding sources (e.g. member dues, governmental/taxes, commercial products		\checkmark
	or services, grants from industry or government).		

If yes to #7, provide name and funding Sources:

If you believe that you do not have a conflict but are concerned that it may appear that you do, you may attach additional sheets explaining why you believe that you should not be excluded.

I certify that I have read and understand this Conflict of Interest Form and that the information I have provided is true, complete, and correct as of this date.

X		2/25/14	Ryan Zehnder
	Signature	Dáte	V Print Name

Feb 2	5 201/	4 03:5	55pm
-------	--------	--------	------

P001/001

Washingto	n Slate	۸	7
Health	Care.	Authority	ŕ

Health Technology Assessment

Disclosure

Any unmarked topic will be considered a "Yes"

	Potential Conflict Type	Yes	No
1.	Salary or payments such as consulting fees or honoraria in excess of \$10,000.		X
2,	Equity interests such as stocks, stock options or other ownership interests.		- X
3,	Status or position as an officer, board member, trustee, owner.	· .	<u>Ý</u>
4.	Loan or intellectual property rights.		X
5,	Research funding.		
6.	Any other relationship, including travel arrangements.		$ \times$

If yes, list name of organizations that relationship(s) are with and for #6, describe other relationship:


	Potential Conflict Type	Yes	No
7.	Representation: if representing a person or organization, include the name and funding sources (e.g. member dues, governmental/taxes, commercial products or services, grants from industry or government).		×

If yes to #7, provide name and funding Sources: _

If you believe that you do not have a conflict but are concerned that it may appear that you do, you may attach additional sheets explaining why you believe that you should not be excluded.

For questions contact: Christine Masters Health Technology Assessment PO Box 42712 Olympia, WA 98504-2712 360-725-5126 360-586-8827(-fox)

Participant_disclosure



Health Technology Assessment

Disclosure

Any unmarked topic will be considered a "Yes"

	Potential Conflict Type	Yes	No
1.	Salary or payments such as consulting fees or honoraria in excess of \$10,000.	<u> </u>	
2.	Equity interests such as stocks, stock options or other ownership interests.		
3.	Status or position as an officer, board member, trustee, owner,	<u> </u>	
4.	Loan or intellectual property rights.	1	
5.	Research funding.	<u> </u>	
6.	Any other relationship, including travel arrangements.		

If yes, list name of organizations that relationship(s) are with and for #6, describe other relationship:

	Potential Conflict Type	Yes	No
7.	Representation: if representing a person or organization, include the name and funding sources (e.g. member dues, governmental/taxes, commercial products or services, grants from industry or government).		\checkmark

If yes to #7, provide name and funding Sources: _____

If you believe that you do not have a conflict but are concerned that it may appear that you do, you may attach additional sheets explaining why you believe that you should not be excluded.

I certify that I have read and u information I have provided is	nderstand this Conflict true, complete, and co	of Interest Form and that the rrect as of this date.
X	2/20/14	sout Buck (
Signature	Date	Print Name
For questions contact: Christine M	acters	
-	nology Assessment	
PO Box 427		
	A 98504-2712	

Washington State Health Care Authority

Health Technology Assessment

Disclosure

From:

Any unmarked topic will be considered a "Yes"

•			
	Potential Conflict Type	Yes	No
1.	Salary or payments such as consulting fees or honoraria in excess of \$10,000.		
2.	Equity interests such as stocks, stock options or other ownership interests.		$\mid X \mid$
3.	Status or position as an officer, board member, trustee, owner.		X
4.	Loan or intellectual property rights.		
5.	Research funding.	· · · · · ·	
6.	Any other relationship, including travel arrangements.		

If yes, list name of organizations that relationship(s) are with and for #6, describe other relationship:

	merican Academy of Pain Medicine Ultrase	malo	sists	-
./	Vorth American Spine Society, ISIS.			
	notienzie Institute USH - Vall travel	Roz	TRad	whing
	or lectures	$\underline{\bigcirc}$		
· ·	Potential Conflict Type	Yes	No	
7.	Representation: if representing a person or organization, include the name and funding sources (e.g. member dues, governmental/taxes, commercial products or services, grants from industry or government).		$-\chi$	

If yes to #7, provide name and funding Sources: ______

. .

If you believe that you do not have a conflict but are concerned that it may appear that you do, you may attach additional sheets explaining why you believe that you should not be excluded.

I certify that I have read and understand this Conflict of Interest Form and that the information I have provided is true, complete, and correct as of this date.

on Stout Print Name Signature Date

Disclosure

Any unmarked topic will be considered a "Yes"

	Potential Conflict Type	Yes	No
1.	Salary or payments such as consulting fees or honoraria in excess of \$10,000.		X
2.	Equity interests such as stocks, stock options or other ownership interests.		X
3.	Status or position as an officer, board member, trustee, owner.		X
4.	Loan or intellectual property rights.		X
5.	Research funding.		
6.	Any other relationship, including travel arrangements.		X

If yes, list name of organizations that relationship(s) are with and for #6, describe other relationship:

	Potential Conflict Type	Yes	No
7.	Representation: if representing a person or organization, include the name and funding sources (e.g. member dues, governmental/taxes, commercial products or services, grants from industry or government).		X

If yes to #7, provide name and funding Sources: _____

If you believe that you do not have a conflict but are concerned that it may appear that you do, you may attach additional sheets explaining why you believe that you should not be excluded.

I certify that I have read and understand this Conflict of Interest Form and that the information I have provided is true, complete, and correct as of this date.

.


Date

Kevin E. Vorenkamp Print Name


For questions contact: Christine Masters Health Technology Assessment PO Box 42712 Olympia, WA 98504-2712 360-725-5126

Signature

Participant_disclosure



Kevin E. Vorenkamp, M.D Virginia Mason Medical Center Seattle, Washington




Alternative Guidance


Multisociety Pain Workgroup (MPW)


- 14 Societies, Chaired by Ray Baker, M.D.
- "The CMDs have asked the MPW to review all of the pain management LCDs, and to make provisions which should be kept and which should be altered or eliminated."
- Facet interventions were the 2nd of several topics reviewed


Facet RFA Recommendations from MPW

- Dual-diagnostic blocks
- >80% Relief
- Contrast verified
- Under multiplanar fluoroscopic imaging, RF cannulae should be placed adjacent and maximally parallel to each of the two medial branch nerves innervating the target joint. This best assures an optimal lesion and subsequent prolonged duration of relief.
- Physician qualifications (edited/added by CMDs)










Lord, et al (NEJM '96)





Lateral (Panel A) and Anteroposterior (Panel B) Radiographs Showing the Insertion of the Electrode along a Parasagittal Plane to Make Lesions over the Lateral Aspect of the Articular Pillar.



Facet RFA (Neurotomy) is THE most effective non-surgical treatment for spinal pain arising from the Facet Joints

Key Points:

- 1. Facet RFA is EFFECTIVE when patients are properly selected with correct procedural technique utilized.
- 2. Multisociety Pain Workgroup has recently reviewed the supportive evidence and made recommendations on proper patient selection and procedural technique. CMDs have made further comments on physician qualifications.
- 3. Spectrum report demonstrates lack of basic knowledge of the procedure analyzed and therefore highlights flaws in the report analysis.



Facet Neurotomy

Clinical Expert

Jason G. Attaman, DO FAAPMR

Disclosure

Any unmarked topic will be considered a "Yes"

	Potential Conflict Type	Yes	No
1.	Salary or payments such as consulting fees or honoraria in excess of \$10,000.		Х
2.	Equity interests such as stocks, stock options or other ownership interests.		Х
3.	Status or position as an officer, board member, trustee, owner.		х
4.	Loan or intellectual property rights.		Х
5.	Research funding.		x
6.	Any other relationship, including travel arrangements.		х

If yes, list name of organizations that relationship(s) are with and for #6, describe other relationship:

	Potential Conflict Type	Yes	No
7.	Representation: if representing a person or organization, include the name and funding sources (e.g. member dues, governmental/taxes, commercial products or services, grants from industry or government).		x

If yes to #7, provide name and funding Sources: ______

If you believe that you do not have a conflict but are concerned that it may appear that you do, you may **attach additional sheets** explaining why you believe that you should not be excluded.

I certify that Lhave read and and and retard this Conflict of Interest Form and that the information I have provided is true, complete, and correct as of this date.			
<u>X</u>		12/5/2013	Jason G Attaman DO
	Signature	Date	Print Name

Curriculum Vitæ

PERSONAL INFORMATION

Jason G. Attaman, DO, FAAPMR

4071 SW Admiral Way #217 Seattle, WA 98116

Phone	(206) 395-4422
Email	doctorattaman@gmail.com
Web	www.jasonattaman.com



EDUCATION

1997-2002	Doctor of Osteopathic Medicine
	Chicago College of Osteopathic Medicine, Downers Grove, Illinois
1991–1994	Bachelor of Arts in English, Graduated with Honors
	University of Michigan, Ann Arbor, Michigan

POSTDOCTORAL TRAINING

2006–2007	ACGME accredited Fellowship; Pain Medicine
	Department of Anesthesiology
	Wayne State University School of Medicine, Detroit, Michigan
2003-2006	ACGME accredited Residency; Physical Medicine and Rehabilitation
	Department of Physical Medicine and Rehabilitation
	University of Michigan Health System, Ann Arbor, Michigan
2002-2003	AOA accredited Internship; Osteopathic Traditional Rotating
	Department of Post-Doctoral Training
	St. Francis Hospital, Evanston, Illinois

WORK EXPERIENCE

2010-2011	Dr. Attaman, PLLC; Seattle, Bellevue, and Auburn, Washington Pain Medicine Physician
	Owner, private practice Interventional Pain Management Clinic
2008-2010	Pacific Medical Centers; Seattle, Washington
	Pain Medicine Physician
	• First and only Pain Medicine subspecialist in a multi-specialty clinic of 144
	health care professionals
	 Built and developed the Pain Medicine department
	• Specified, built and developed an interventional fluoroscopy suite in the ambulatory surgery center (ASC)
	 Supervised and trained staff including an ARNP, RNs, MAs, and scheduler
	• Wrote departmental policies

• Exceeded productivity goals

BOARD CERTIFICATION

- 2007 *Diplomate & Fellow*, American Board of Physical Medicine and Rehabilitation; certificate #8479
- 2007 *Subspecialty Certificate in Pain Medicine,* American Board of PM&R via the American Board of Anesthesiology; certificate #1123
- 2007 American Board of Electrodiagnostic Medicine; board eligible

LICENSURE

2003	National Board of Osteopathic Medical Examiners Levels I, II, and III
9/18/2006	Michigan Board of Osteopathic Medicine and Surgery #5101015807
9/18/2006	Michigan Board of Pharmacy Controlled Substance License #5315028991
8/30/2006	DEA Controlled Substance Registration Certificate, schedules 2, 2N, 3, 3N, 4, 5
1/23/2007	Washington Osteopathic Physician & Surgeon Prescriptive License #OP00002165

HOSPITAL AND SURGERY CENTER APPOINTMENTS

- 2010 Attending Physician, Overlake Hospital, Bellevue, Washington
- 2010 Attending Physician, Auburn Regional Hospital, Auburn, Washington
- 2010 Attending Physician, Overlake Surgery Center, Bellevue, Washington
- 2008 Attending Physician, Swedish Hospital, Seattle, Washington
- 2008 Attending Physician, Seattle Surgery Center, Seattle, Washington

COMMITTEES

2010 Overlake Surgery Center, Bellevue, WashingtonMedical Executive Committee member

AWARDS

- 2009 "Excellence in Clinical Team Work and Quality Performance," awarded by the administration of Pacific Medical Centers, Seattle, Washington
- 2006 "Superstar Physician Award" for outstanding teamwork, awarded by rehabilitation nurses of the University of Michigan Health System, Ann Arbor, Michigan
- 2004 "Superstar Physician Award" for outstanding patient satisfaction, awarded by inpatients of the University of Michigan Health System, Ann Arbor, Michigan

PROFESSIONAL SOCIETIES

- 2007 American Academy of Interventional Spine Specialists
- 2007 American Medical Association
- 2006 North American Spine Society
- 2006 International Spinal Intervention Society
- 2006 American Society of Interventional Pain Physicians
- 2003 American Academy of Physical Medicine and Rehabilitation
- 2002 Association of American Physicians and Surgeons
- 1998 American Association of Orthopædic Medicine
- 1997 American Osteopathic Association
- 1997 American Academy of Osteopathy

GRAND ROUNDS

- Attaman JG "Neuromodulation for Chronic Pain," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan
 Attaman JC "The Pain Shore Neuro" Department of Physical Medicine and
- 2005 Attaman JG "The Pain-Sleep Nexus," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan

LECTURES

2008 Attaman JG "Overview of Interventional Pain Management Procedures with CME credit," quarterly staff meeting, Pacific Medical Centers, Seattle, Washington 2008 Attaman JG "New Developments in Interventional Pain Management," board of directors meeting, Pacific Medical Centers, Seattle, Washington 2006 Attaman JG "Spinal Cord Vascular Anatomy and Vascular Complications of Spinal Procedures," Department of Anesthesiology, Wayne State University, Detroit, Michigan 2006 Attaman JG "Pain M&M: Vascular Uptake During Cervical Medial Branch Blocks," Department of Anesthesiology, Wayne State University, Detroit, Michigan 2006 Attaman JG "Radiation Safety for Pain Physicians," Department of Anesthesiology, Wayne State University, Detroit, Michigan 2006 Attaman JG "The Pain-Sleep Nexus," Department of Anesthesiology, Wayne State University, Detroit, Michigan 2006 Attaman JG "Spine Anatomy Parts I&II" Department of Anesthesiology, Wayne State University, Detroit, Michigan Attaman JG "Pain Morbidity and Mortality," Department of Anesthesiology, Wayne State 2006 University, Detroit, Michigan 2006 Attaman JG "Pain Morbidity and Mortality," Department of Anesthesiology, Wayne State University, Detroit, Michigan 2006 Attaman JG "Pain Morbidity and Mortality," Department of Anesthesiology, Wayne State University, Detroit, Michigan 2005 Attaman JG "Spine Anatomy," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan 2005 Attaman JG: "Peripheral Nerve Injuries in Musicians," Departments of Physical Medicine and Rehabilitation and Neurology, University of Michigan Health System, Ann Arbor, Michigan 2005 Attaman JG: "Applying to Pain Medicine Fellowships," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan 2005 Attaman JG, Farhat, RF: "M&M Conference," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan 2004 Attaman JG: "Occupational Low Back Pain," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan 2004 Attaman JG: "Dr. Ted Cole Day Lecture: Clinical Predictors of PT Outcomes in Low Back Pain Patients," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan 2004 Attaman JG: "Traumatic Brachial Plexopathy; Diagnosis, Surgical Intervention, and Rehabilitation," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan 2003 Attaman JG: "Physiotherapeutic Techniques in Stroke Rehabilitation," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor,

Michigan

LECTURES CONTINUED

- 2003 Attaman JG: "The History of Ritual Genital Surgery," Department of Obstetrics and Gynecology, St. Francis Hospital, Evanston, Illinois
- 2003 Attaman JG: "Roentgenographic Characteristics of Achondroplastic Dwarfism," Department of Radiology, St. Francis Hospital, Evanston, Illinois

WORKSHOP TEACHING

- 2006 Colwell MO, Attaman JG, Farhat RF, et al.: "Resident Chair and Table Trainer: Introduction to Manual Medicine," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan
- 2005 Colwell MO, Attaman JG, et al.: "Table Trainer: Introduction to Manual Medicine," Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan

MEDICAL SCHOOL TEACHING

- 2006 Supervising and teaching fellow to Wayne State University anesthesiology residents and medical students on rotation to the pain medicine service
- 2004 Attaman JG: "Gait Analysis Workshop for the Medical Student," University of Michigan Medical School, Ann Arbor, Michigan
- 2004 Supervising House Officer to University of Michigan Medical School students on clinical rotation in the Department of Physical Medicine and Rehabilitation, University of Michigan Health System, Ann Arbor, Michigan
- 2003 Supervising House Officer to University of Illinois Medical School students, Department of General Surgery, St. Francis Hospital, Evanston, Illinois

CONTINUING MEDICAL EDUCATION WORKSHOPS

- 2010 Depuy Spine: "Vertebral Body Augmentation Training With Cadaver Workshop," San Diego, California. February 4.
- 2009 Baylis Medical: "Radiofrequency Lesioning: Intervertebral Disc Biacuplasty, Sacroiliac Joint Neurotomy, and Thoracic Z-Joint Neurotomy," San Carlos, California. November 7.
- 2009 American Academy of Pain Medicine: "AAPM 25th Annual Meeting," Honolulu, Hawaii. January 28–31.
- 2008 International Spine Intervention Society: "ISIS 16th Annual Scientific Meeting," Las Vegas, Nevada. July 23–26.
- 2008 International Spine Intervention Society: "ISIS Electroneuromodulation Workshop," British Columbia, Canada. February 16–17.
- 2007 Wayne State University and University of Michigan Schools of Medicine: "Advanced Regional Anesthesia 2007: Invasive Pain Management Techniques and Ultrasound Guided Regional Anesthesia Hands-on Workshop with Live Models and Cadavers," Detroit, Michigan. May 4–6, 2007.
- 2006 Advanced Neuromodulation Systems: "Private training in peripheral nerve field stimulation with Dr. Greaser," Fredericksburg, Virginia. October 13.
- 2006 Advanced Neuromodulation Systems: "Spinal Cord Stimulation Cadaver Workshop," Memphis, Tennessee. October 27-29.
- 2006 Medtronic: "Spinal Cord Stimulation Cadaver Workshop," Denver, Colorado. November 4-5.

CONTINUING MEDICAL EDUCATION WORKSHOPS CONTINUED

- 2006 Parallax Medical, Inc.: "Percutaneous Vertebroplasty (with Cadaver and Fluoroscopy) Workshop," Ann Arbor, Michigan.
- 2004 Parallax Medical, Inc.: "Percutaneous Vertebroplasty (with Cadaver and Fluoroscopy) Workshop," Ann Arbor, Michigan. March 13.
- 2001 Fédération Internationale de Médecine Manuelle (FIMM): "13th Triennial International Congress of Integrative Manual Medicine and Workshops," Chicago, Illinois. July 23-27.
- 2001 The Cranial Academy: "Advanced Instructor Workshop with Fred Mitchell, JR, DO, FAAO, FCA," Chicago, Illinois. April 26-29.
- 2000 American Academy of Osteopathy: "2000 Annual Convocation and Manual Medicine Workshops," Cleveland, OH. March 22-26.
- 1999 American Academy of Neural Therapy: "German Neural Therapy According to Dr. Huneke Workshop with Robert Kidd, MD," Chicago, Illinois. May 7-8.
- 1999 American Association of Orthopædic Medicine: "Introduction to Prolotherapy Lectures and Cadaver Workshop," Chicago, Illinois. June 11-12.
- 1999 American Academy of Osteopathy: "1999 Annual Convocation and Manual Medicine Workshops," St. Louis, MO. March 25-28.
- 1999 Jim Jealous, DO: "Introduction to Biodynamic Osteopathy," Franconia, NH.
- 1999 Chicago College of Osteopathic Medicine: "Percussion Hammer Technique Workshop," Chicago, Illinois.
- 1998 University of Wisconsin Medical School: "The Anatomy, Diagnosis, and Treatment of Chronic Myofascial Pain with Prolotherapy Cadaver and Live Patient Workshop," Madison, Wisconsin. October 12-14.
- 1998 American Academy of Osteopathy: "1998 Annual Convocation and Manual Medicine Workshops," Colorado Springs, CO. March 26-29.
- 1998 The Cranial Academy: "Basic Course in Osteopathy in the Cranial Field Workshop," Chicago, Illinois.
- 1997 Chicago College of Osteopathic Medicine: "Facilitated Positional Release Workshop with Eileen DiGiovanna, DO," Chicago, Illinois.

MENTORING

- 2002 The Student Doctor Network (click here to visit SDN) (http://forums.studentdoctor.net/forumdisplay.php?f=132) Advisor for the Pain Medicine and PM&R discussion forums;
 - Give career advice for medical students, interns and residents interested in the specialties of Pain Medicine and PM&R:
 - Contributor to the Pain Medicine and PM&R frequently asked questions (FAQ) document

BIBLIOGRAPHY

- 2005 Tong HC, HO SG, Attaman JG, Geisser ME. Central Sensitization of Pressure Pain Thresholds. *Submitted to the European Journal of Pain*.
- 2005 Farhat RP, Attaman JG, Haig AJ. Electrodiagnostic Evidence of Long Thoracic Mononeuropathy After Cervical Transforaminal Epidural Injection. *Submitted to Spine*.

BIBLIOGRAPHY CONTINUED

2005 Tong HC, Attaman JG, HO SG, Geisser ME. Pain Pressure Threshold at the Low Back and the Deltoid in Subjects with Low Back Pain. Pending submission.

PAIN PROCEDURE COMPETENCY

Head: greater and lesser occipital nerve block, supraorbital nerve block, infraorbital nerve block, gasserian ganglion block, sphenopalatine ganglion block, maxillary nerve block

Neck: cervical medial branch block and radiofrequency lesioning, cervical interlaminar epidural block, cervical epidural catheter, zygapophyseal block, superficial cervical plexus block

Thorax: thoracic interlaminar epidural, thoracic transforaminal block, thoracic paravertebral block, thoracic medial branch block and radiofrequency lesioning (traditional and with Baylis ThoraCool system), thoracic intraarticular zygapophyseal joint blocks, intercostal nerve block under fluoroscopy with contrast, intercostal neurolysis and radiofrequency lesioning

Lumbar Region: transforaminal epidural blocks, selective nerve root blocks, interlaminar epidural blocks, transforaminal lateral recess blocks, medial branch blocks and radiofrequency lesioning, intraarticular zygapophyseal joint blocks, pulsed radiofrequency of the dorsal root ganglion, pars defect blocks, hardware screw blocks, discography, functional anesthetic discography,

Baylis TransDiscal cooled radiofrequency biacuplasty, percutaneous intradiscal coblation nucleoplasty, caudal epidural block, lumbar epidurolysis (Racz technique), sacroiliac joint injection and radiofrequency lesioning (traditional and Baylis SInergy system)

Joint Injections: shoulder joint injection, subacromial injection, olecranon bursa injection, hip injection under fluoroscopy, knee injection, trochanteric bursa injection under fluoroscopy, ischial bursa injection, knee injection, ankle joint injection, acromioclavicular joint block, pubic symphysis block under fluoroscopy, xiphisternal block under fluoroscopy

Peripheral Nerve Blocks: suprascapular nerve block and pulsed radiofrequency, median nerve block at the wrist, ulnar nerve block at the wrist, digital nerve block, axillary block with nerve stimulation and ultrasonic guidance, superficial cervical plexus block, ilioinguinal nerve block and pulsed radiofrequency, lateral femoral cutaneous block, genitofemoral nerve block, common peroneal nerve block, genital nerve block, saphenous nerve block, ankle block

Sympathetic System: stellate ganglion block, T2 and T3 thoracic sympathetic block, splanchnic block and neurolysis, celiac plexus block and neurolysis, lumbar sympathetic block and radiofrequency lesioning, hypogastric plexus block and neurolysis, ganglion impar block

Implantable Devices: spinal cord and peripheral nerve field stimulator percutaneous trial and surgical implantation, intrathecal pump trial and surgical implantation, tunneled epidural and intrathecal catheters, continuous peripheral nerve catheters

Platelet Rich Plasma injection therapy under image guidance


Prolotherapy under image guidance


ELECTRODIAGNOSTIC PROCEDURES


Electromyography Nerve Conduction Studies •Over 200 *complete* electrodiagnostic studies performed during residency •All studies supervised by Diplomates of the American Board of Electrodiagnostic Medicine


MISCELLANEOUS


Born in Rochester, Michigan



















		Facet Neurotomy
O'Neill and Ov	vens, Spir Editor	ne J; 2009: 9:619-22 rial
Reanalysis of comp	arative bloc	k data (Lord SM, et al)
Concordant response	18% (3/16)	±18.83%; -0.83%-36.83%
Discordant response	35% (6/17)	±22.67%; 12.33%–57.67%
Likely that spread responses.	l of anesthet	ic creates false positive
		Washington State Health Care Auth













			Face	t Neuroto
Current Sta	te Age	ncy F	Policy	1
Description	Medicaid	UMP	DOC	LNI
Diagnostic Medial Branch Nerve Blocks	PA	PA	PA	PA
Facet Neurotomy	PA	PA	PA	PA
C: Covered NC: Not covere PA: Prior autho	-	quired		
				Wpsgington Sta Health Ca



	State Agency Utilization					
F	Facet Neurotomy					
All Agencies Facet Neurotomies, Paid \$	2009	2010	2011	2012	4 Yr Overall Total	
Facet Neurotomy Patients	611	602	606	236	1785	
Facet Neurotomy Procedures (encounters)	769	773	814	274	2630	
Avg Encounters per Patient	1.3	1.3	1.3	1.2	1.5	
Total Paid	\$1,332,995	\$1,154,223	\$1,233,502	\$489,296	\$4,210,015	
Avg Paid per Procedure	\$1,733	\$1,493	\$1,515	\$1,785	\$1,600	

State Agency Utilization Facet Neurotomy				
Overall (4 year) Averages by Agency	PEB/UMP Primary	L&I	Medicaid (Non- Medicare)	
Average Paid per Encounter	\$2,799	\$2,507	\$844	
Average Encounters per Patient	1.6	1.3	1.5	
Average Facets per Encounter	2.7	2.5	2.4	


		State Age	ncy Utiliz
	iagnoses by Agency, ved \$ Descending	Allowed \$	% of Total
PEB/UMP	Overall Allowed Total:	\$1,214,721	
Lumbosacral sp	ondylosis	\$456,063	37.5%
Lumbago		\$157,157	12.9%
Cervical spondy	losis	\$154,892	12.8%
Other back sym	ptoms	\$85,669	7.1%
L&I	Overall Allowed Total:	\$1,333,133	
Lumbosacral sp	ondylosis without myelopathy	\$241,941	18.1%
Lumbar sprain a	and strain	\$247,025	18.5%
Other symptom	is referable to back	\$136,023	10.2%
Lumbago		\$118,548	8.9%
Medicaid	Overall Allowed Total:	\$731,903	
Lumbosacral sp	ondylosis	\$312,280	42.7%
Lumbago		\$96,163	13.1%
Chronic pain NE	EC	\$81,529	11.1%
Cervical spondy	losis	\$57,982	7.9%




State Agency Utilization Repeated Facet Neurotomy Use 2009-2012					
PEB/UMP Neurotomy Encounters	Patient Count	% Total Patients	Medicaid Neurotomy Encounters	Patient Count	% Total Patients
10	1	0.2%	13	1	0.2%
6	5	0.8%	6	7	1.3%
5	10	1.5%	4	9	1.6%
4	16	2.5%	3	27	4.9%
3	39	6.0%	2	129	23.2%
2	156	23.9%	1	380	68.5%
1	425	65.2%			
L&I Neurotomy	Patient	% Total			
Encounters	Count	Patients			
5	1	0.2%			
4	4	0.6%			
3	8	1.2%			
2	182	28.1%			
1	452	69.9%			


		State Ag	ency Utilizatio
Per Procedure Avg Allowed Charges by Agency, Setting and Payer (Non-Medicare)	PEB/UMP Primary (n=435*)	L&I (n=815*)	Medicaid Non-Medicare (n=718*)
Breakdown 1			
Professional Services	\$649	\$1,307	\$224
Facility/Other	\$1,246	\$1,090	\$689
Breakdown 2			
Neurotomy	\$1,739	\$1,494	\$838
Imaging/Guidance	\$71	\$61	\$3
Diagnostic Injections*	\$62	\$778	\$56
Other	\$22	\$64	\$16
Avg Allowed/Procedure	\$1,895	\$2,397	\$913






Facet Neurotomy Pain Log
Medical Treatment Guidelines Washington State Department of Labor and Industries Facet neurotomy workup pain relief report form
<u>Directions</u> : This form is to be completed by the patient, or someone recording the patient's responses, in "real time" following the administration of a facet block. Pain relief level should be recorded while doing activities that previously caused pain . Please fill in the date and time of your block was performed, then circle the time the block was completed on the time chart. Every 15 minutes put a check mark in the time chart box that most accurately describes the degree of your pain following the block. This form needs to be returned to the physician who performed your block at your next scheduled visit, since it will become part of your medical record.
Name: Date of block: Time of block
My pain Is: Time (S): Form of the Media Strong and Strong and Strong Strong and Strong Stron
6.00 4.00 6.04 4.00 9.05 4.04 9.04 5.00 µm 9.05 6.16 9.09 5.16 9.05 5.46
1000an 669 pn 0015 615 0016 616 1016 616 1016 616 1100an 789 pn
11.30 7.50 11.45 7.16 12.15 7.65 12.15 5.15 12.15 5.19
12:45 5:45 1:40 pm 9:06 pm 1:15 9:15 1:30 9:20 1:45 9:45 1:46 9:45 1:49 pm 10:06 pm
215 10:15 2:39 10:39 3:09 pm 11:09 3:09 pm 11:09 3:01 11:15 21:00
3:30 11:30 3:45 11:45
















Questions?	
More Information: http://www.hca.wa.gov/hta/Pages/neurote Gary Franklin, MD, MPH Medical Director Washington State Department of Labor & I <u>FRAL235@LNI.WA.GOV</u>	
29	Washington State Health Care Authority



























Overall	quality of evidence (GRADE)
Quality rating	Interpretation
High	High confidence that the evidence reflects the true effect.
Moderate	Moderate confidence in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low	Confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Insufficient	Very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect.










(Lumbar: FN following selection by diagnostic block)								
Short-term pain & function	Studies N	F/U	Diagnostic Method		≥ 80% pain relief ^{tients}	Overall QoE	Favor	
Back pain "success" (≥50% pain relief)	2 retro cohort studies N = 313	6 mos.	MBB	52-54%	56-84%	Insufficient	≥80% pai relief fron block in 1/2 studio	
"Success" composite (VAS, GPE) following RFN	2 cohort (1 prosp, 1 retro) studies N = 113	3 mos.	MBB	35-67%	56-76^	Insufficient	≥80% pai relief from block in 1/2 studio	
Function "success" (≥50% improvement in activity levels)	1 retro cohort study N = 51	6 mos.	MBB	33%	76%	Insufficient	≥80% pai relief froi block	

KQ	Summary	Result	Overall Quality of Evidence	Evidence basis			
KQ1a	Diagnostic block versus physical exam (lumbar spine)	No difference in pain relief "success" between groups.	Low	1 RCT N = 70 3 months			
KQ1b	MBB versus pericapsular block (lumbar spine)	No difference in pain or function between groups.	Low	1 RCT N = 26 6 months			
KQ1c	1 MBB versus 2 comparative MBBs (lumbar spine)	No difference in pain between groups.	Low	1 RCT N = 33 3 months			
KQ1d	Threshold of pain relief (50-79% versus ≥80%) following block (lumbar spine)	Inconclusive; no difference OR favors ≥80% pain relief	Insufficient	2 retro cohorts N = 313 6 mos.			




	(Lu		KQ2: Ef	sus sham	neurotomy))
Interver	paties ntion:	nts total (31	– 81 per study s sham neurotomy			
RCT	N	Follow-up	Duration of symptoms	Diagnostic Block	% pain relief required for FN	Outcomes blinded?
Van Kleef (1999)	31	2 mos.	25 (12-120) mos.	1 MBB	≥ 50% pain relief	yes
Leclaire (2001)*	70	3 mos.	> 3 mos.	1 IAB	"significant" response	yes
van Wijk (2005)	81	3 mos.	> 6 mos.	2 IABs	$\geq 50\%$ pain relief	yes
Gallagher (1994)	30	6 mos.	> 3 mos.	1 IAB	"good" response	yes
Nath (2008)	40	6 mos.	≥ 24 mos.	2 MBBs	≥ 80% pain relief	yes
Tekin (2007)	40	6 mos. 12 mos.	> 72 mos.	1 MBB	≥ 50% pain relief	yes


(Lumbar		Q2: Eff	•	neuroto	omy)	
Short-term	Studies		Diagnostic block	RFN	Sham	Overall	
Pain	N	F/U	(% pain relief required for FN)	∆ from l (mear		QoE	Favors
Back pain (VAS, 0-100)	6 RCTs N = 292	2-6 mos.	Varied (varied)	-0.4 to 42.0 (-1 to 65%)		Low	neither (4/6 studies)
McGill pain (0-50)	1 RCT N = 30	6 mos.	1 IAB ("good" response)	3 ± 5.5	2 ± 1.9	Low	neither
Leg pain (VAS, 1-100)	2 RCTs N = 121	3-6 mos.	Varied (varied)	16 to 21 (37 to 50%)	1 to 16 (5 to 25%)	Low	RFN
Generalized pain (VAS, 1-100)	1 RCT N = 40	6 mos.	2 MBBs (≥80%)	19.3 (32%)	3.7 (9%)	Low	RFN


KQ2: Efficacy (Lumbar spine: RF versus sham neurotomy)							
Short-term Pain	Studies N	F/U	Diagnostic block (% pain relief required for FN)	RFN % pat	Sham	Overall QoE	Favors
Back pain "success" (VAS, ≥50% pain relief)	1 RCT N = 81	3 mos.	2 IABs (≥50%)	33%	34%	Low	neither
Back pain "success" (GPE, ≥50% improvement)	1 RCT N = 81	3 mos.	2 IABs (≥50%)	62%	39%	Low	RFN (marginally)
Leg pain "success" (VAS, ≥50% pain relief)	1 RCT N = 81	3 mos.	2 IABs (≥50%)	50%	37%	Low	neither


KQ2: Efficacy (Lumbar spine: RF versus sham neurotomy)								
Short-term	Studies N		Diagnostic block	RFN	Sham	Overall		
Function		F/U	(% pain relief required for FN)	∆ from baseline (mean (%))		QoE	Favors	
Function (ODI, 0-100)	3 RCTs N = 141	2-6 mos.	Varied (varied)	4.7 to 14.1 (12 to 36%)		Low	RFN (2/3 studies)	
Function (Roland-Morris, converted to 0-100)	1 RCT N = 70	3 mos.	1 IAB ("significant" response)	9.8 ± 19.5 (19%)	7.2 ± 17.0 (14%)	Low	neither	
Disability (Waddell, 0-24)	1 RCT N = 31	2 mos.	1 MBB (≥50%)	0.33	0.07	Low	neither	


T			22) -				
Long-term Pain &			Diagnostic block	RFN	Sham	011	
Function	Studies N	F/U	(% pain relief required for FN)	∆ from l (mear		Overall QoE	Favor
Back pain (VAS, 0-100)	1 RCT N = 40	12 mos.	1 MBB (≥50%)	41.0 ± 9.1 (63%)		Low	RFN
Function (ODI, 0-100)	1 RCT N = 40	12 mos.	1 MBB (≥50%)	11.2 ± 4.8	6.5 ± 3.9	Low	RFN










































KQ3: Safety (Lumbar spine: RF versus sham neurotomy)								
	Studies N	RFN % pa	Sham	RR (95% CI) RD (95% CI)	Overall QoE	Favors		
Treatment – related pain (moderate or severe)	1 RCT N = 81	59%	36%	1.40 (0.95, 2.04) 0.09 (-0.01, 0.20)	Low	neither		
Treatment – related sensibility changes	1 RCT N = 81	5%	0%	1.31 (0.74, 2.31) 0.41 (-0.04, 0.13)	Low	neither		
Treatment – related motor changes	1 RCT N = 81	0%	2%	0.0 (NC) -0.02 (-0.07, 0.02)	Low	neither		
Treatment – related adverse events (undefined)	4 RCTs N = 191	0%	0%	NC	Low	neither		










		spine	: RF versu	5 511a111	neurou		
				RFN	Sham		
	Studies N	F/U	Subgroup	achieved	nts who "success" oosite	Overall QoE	Outcome
Sex	1 RCT	3 mos.	Male	20%	43%	Low	No modificatio
	N = 81		Female	30%	21%		of treatment effect
Age			18-40 years	31%	33%		
			>41 years	26%	28%		
Duration of pain			2-5 years	32%	33%		
			>5 years	24%	25%		
Employment			Employed	30%	35%		
status			Unemployed	24%	24%		





Short-term	Studies		Diagnostic block	RFN	Sham	Overall	
function		F/U	(% pain relief required for FN)	∆ from] (mear	baseline 1 (%))	QoE	Favors
Function (ODI, 0-100)	2 RCTs N = 71	2-6 mos.	1 MBB (≥50%)	11 to 14	-2 to 11	Low	RFN (2/2 studies
Function (Waddell, 0-24)	1 RCT N = 31	2 mos.	1 MBB (≥50%)	0.33	0.07	Low	neither
0-24)							











	Summary: Efficacy (KQ2): RFN versus Sham, Lumbar spine					
KQ	Outcome	Result	Overall Quality of Evidence	Evidence basis		
KQ2	Short-term back pain (VAS)	No difference between groups (4/6 studies)	Low	6 RCTs N = 292 2-6 mos.		
KQ2	Short-term pain (leg, generalized, GPE "success")	Favors RFN	Low	\leq 2 RCTs N \leq 121 3-6 mos.		
KQ2	Short-term pain (VAS back pain "success", leg pain "success", McGill pain)	No difference between groups	Low	1 RCT each N = 31 or 81 3-6 mos.		
KQ2	Short-term function (ODI)	Favors RFN (2/3 studies)	Low	3 RCTs N = 141 2-6 mos.		
KQ2	Short-term function (Roland-Morris, Waddell, physical activity)	No difference between groups	Low	1 RCT each N = 31-81 2-3 mos.		
KQ2	Long-term pain (VAS) & function (ODI)	Favors RFN	Low	1 RCT N = 40 12 mos.		

RF	Summary: Efficacy (KQ2): RFN versus Spinal Injections, Lumbar spine						
KQ	Comparator	Outcome	Result	Overall Quality of Evidence	Evidenc e basis		
KQ2	MBB or IAI	Short-term back pain (VAS)	No difference between groups	Low	2 RCTs N = 156 6 mos.		
KQ2	MBB	Short-term back pain "success"	Favors RFN	Low	1 RCT N = 100 6 mos.		
KQ2	IAI	Short-term function (ODI, Roland Morris)	No difference between groups	Low	1 RCT N = 56 6 mos.		
KQ2	MBB	Long-term back pain (VAS)	No difference between groups	Low	1 RCT N = 100 12 mos.		

Summary: Efficacy (KQ2): Cervical spine						
KQ	Outcome	Result	Overall Quality of Evidence	Evidence basis		
RFN ve	ersus Sham					
KQ2	Short-term freedom from accustomed pain	Favors RFN	Low	1 RCT N = 24 6 mos.		
RFN ve	ersus GON injection					
KQ2	Short-term headache pain (VAS)	No difference between groups	Low	1 RCT N = 30 2 mos.		

Summary: Efficacy (KQ4) with MBB selection
RFN versus Sham, Lumbar spine

Dutcome	Result	Overall Quality of Evidence	Evidence basis		
Subgroup of studies from KQ2: patients selected by MBB (≥50% pain relief required)					
Short-term back pain (VAS)	Favors RFN (3/3 studies)	Low	3 RCTs N = 111 2-6 mos.		
Short-term pain (leg, generalized VAS)	Favors RFN	Low	1 RCT N = 40 6 mos.		
Short-term function (ODI)	Favors RFN (2/2 studies)	Low	2 RCTs N = 71 2-6 mos.		
Short-term function (Waddell)	No difference between groups	Low	1 RCT each N = 31 2 mos.		
Long-term pain (VAS) & function (ODI)	Favors RFN	Low	1 RCT N = 40 12 mos.		

53					
Dutcome	Result	Overall Quality of Evidence	Evidence basis		
Subgroup of studies from KQ	2: patients selected by MBB (≥	50% pain relief require	ed)		
RFN versus sham, cervical sp	oine				
Short-term freedom from accustomed pain	Favors RFN	Low	1 RCT N = 24 6 mos.		
RFN versus therapeutic intra	n-articular injection, lumbar sp	ine			
Short-term back pain VAS)	No difference between groups	Low	1 RCT N = 56 6 mos.		
Short-term function ODI, Roland Morris)	No difference between groups	Low	1 RCT N = 56 6 mos.		

(54)					
KQ	Spinal region	Gaps in evidence			
KQ1b	Any	Outcomes following FN in patients selected by MBB vs. IAI blocks			
KQ1	Cervical	Comparative studies evaluating outcomes following FN in patients selected by different diagnostic methods			
KQ2	Cervical	FN versus IAI or MBB in the cervical spine			
KQ4	Any	Differential effectiveness of neurotomy versus spinal injections in subgroups			
KQ5	Any	Full economic analyses evaluating the cost-effectiveness of facet neurotomy compared with other treatment options			
All	Thoracic	Comparative studies evaluating the efficacy, effectiveness, or safety of facet neurotomy			



HTCC Coverage and Reimbursement Determination Analytic Tool

HTA's goal is to achieve *better health care outcomes* for enrollees and beneficiaries of state programs by paying for proven health *technologies that work*.

To find best outcomes and value for the state and the patient, the HTA program focuses on three questions:

- 1. Is it safe?
- 2. Is it effective?
- 3. Does it provide value (improve health outcome)?

The principles HTCC uses to review evidence and make determinations are:

Principle One: Determinations are Evidence based

HTCC requires scientific evidence that a health technology is safe, effective and cost-effective¹ as expressed by the following standards²:

- Persons will experience better health outcomes than if the health technology was not covered and that the benefits outweigh the harms.
- The HTCC emphasizes evidence that directly links the technology with health outcomes. Indirect evidence may be sufficient if it supports the principal links in the analytic framework.
- Although the HTCC acknowledges that subjective judgments do enter into the evaluation of evidence and the weighing of benefits and harms, its recommendations are not based largely on opinion.
- The HTCC is explicit about the scientific evidence relied upon for its determinations.

Principle Two: Determinations result in health benefit

The outcomes critical to HTCC in making coverage and reimbursement determinations are health benefits and harms³:

- In considering potential benefits, the HTCC focuses on absolute reductions in the risk of outcomes that people can feel or care about.
- In considering potential harms, the HTCC examines harms of all types, including physical, psychological, and non-medical harms that may occur sooner or later as a result of the use of the technology.
- Where possible, the HTCC considers the feasibility of future widespread implementation of the technology in making recommendations.
- The HTCC generally takes a population perspective in weighing the magnitude of benefits against the magnitude of harms. In some situations, it may make a determination for a technology with a large potential benefit for a small proportion of the population.
- In assessing net benefits, the HTCC subjectively estimates the indicated population's value for each benefit and harm. When the HTCC judges that the balance of benefits and harms is likely

¹ Based on Legislative mandate: See RCW 70.14.100(2).

² The principles and standards are based on USPSTF Principles at: http://www.ahrq.gov/clinic/ajpmsuppl/harris3.htm

³ The principles and standards are based on USPSTF Principles at: http://www.ahrq.gov/clinic/ajpmsuppl/harris3.htm

to vary substantially within the population, coverage or reimbursement determinations may be more selective based on the variation.

• The HTCC considers the economic costs of the health technology in making determinations, but costs are the lowest priority.

Using Evidence as the Basis for a Coverage Decision

Arrive at the coverage decision by identifying for Safety, Effectiveness, and Cost whether (1) evidence is available, (2) the confidence in the evidence, and (3) applicability to decision.

1. Availability of Evidence:

Committee members identify the factors, often referred to as outcomes of interest, that are at issue around safety, effectiveness, and cost. Those deemed key factors are ones that impact the question of whether the particular technology improves health outcomes. Committee members then identify whether and what evidence is available related to each of the key factors.

2. Sufficiency of the Evidence:

Committee members discuss and assess the evidence available and its relevance to the key factors by discussion of the type, quality, and relevance of the evidence⁴ using characteristics such as:

- Type of evidence as reported in the technology assessment or other evidence presented to committee (randomized trials, observational studies, case series, expert opinion);
- The amount of evidence (sparse to many number of evidence or events or individuals studied);
- Consistency of evidence (results vary or largely similar);
- Recency (timeliness of information);
- Directness of evidence (link between technology and outcome);
- Relevance of evidence (applicability to agency program and clients);
- Bias (likelihood of conflict of interest or lack of safeguards).

Sufficiency or insufficiency of the evidence is a judgment of each clinical committee member and correlates closely to the GRADE confidence decision.

Not Confident	Confident
Appreciable uncertainty exists.	Very certain of evidentiary support.
Further information is needed or	Further information is unlikely to
further information is likely to	change confidence
change confidence.	

⁴ Based on GRADE recommendation: <u>http://www.gradeworkinggroup.org/FAQ/index.htm</u>.

3. Factors for Consideration - Importance

At the end of discussion a vote is taken on whether sufficient evidence exists regarding the technology's safety, effectiveness, and cost. The committee must weigh the degree of importance that each particular key factor and the evidence that supports it has to the policy and coverage decision. Valuing the level of importance is factor or outcome specific but most often include, for areas of safety, effectiveness, and cost:

- Risk of event occurring;
- The degree of harm associated with risk;
- The number of risks; the burden of the condition;
- Burden untreated or treated with alternatives;
- The importance of the outcome (e.g. treatment prevents death vs. relief of symptom);
- The degree of effect (e.g. relief of all, none, or some symptom, duration, etc.);
- Value variation based on patient preference.

Medicare Coverage and Guidelines

From pages 120-125 of the evidence report

Table 5. Overview of payer technology assessments and policies for facet neurotomy

Payer (year)	Lit search dates	Evidence base available [*]	Policy	Rationale/comments
CMS	None	None	None	 There are currently no National Coverage Decisions (NCDs) published from the Centers for Medicare and Medicaid Services (CMS).
Aetna (2013) <i>Clinical Policy</i> <i>Bulletin:</i> <i>Back Pain -</i> <i>Invasive</i> <i>Procedures</i> POLICY #: 0016 Effective Date: 07/31/1995 Last Review Date: 03/19/2013 Next Review Date: 01/09/2014	NR	NR ("Various Studies")	 <u>Non-pulsed radiofrequency facet denervation</u> (also known as facet neurotomy, facet rhizotomy, or articular rhizolysis) is considered medically necessary for treatment of members with intractable cervical or back pain with or without sciatica in the outpatient setting when <i>all</i> of the following are met: Member has experienced severe pain limiting activities of daily living for at least 6 months; <i>and</i> Member has had no prior spinal fusion surgery; <i>and</i> Neuroradiologic studies are negative or fail to confirm disc herniation; <i>and</i> Member has no significant narrowing of the vertebral canal or spinal instability requiring surgery; <i>and</i> Member has tried and failed conservative treatments such as bed rest, back supports, physiotherapy, correction of postural abnormality, as well as pharmacotherapies (e.g., anti-inflammatory agents, analgesics and muscle relaxants); <i>and</i> 	 Only 1 treatment procedure per level per side is considered medically necessary in a 6-month period. <i>Radiofrequency Facet Denervation</i> Percutaneous radiofrequency facet denervation, also known as radiofrequency facet joint rhizotomy or facet neurotomy, involves selective denervation using radiofrequency under fluoroscopic guidance <i>Facet Chemodenervation/Chemical Facet Neurolysis and Laser Facet Denervation</i> The use of chemical facet injections such as alcohol, phenol and hypertonic saline has been proposed as an option for lumbar facet pain. However, there is a lack of published data to support the safety and effectiveness of this technique.

Payer (year)	Lit search dates	Evidence base available [*]	Policy	Rationale/comments
			 <u>Non-pulsed radiofrequency facet denervation</u> is considered experimental and investigational for all other indications because its effectiveness for indications other than the ones listed above has not been established. Aetna considers <i>any</i> of the following injections or procedures experimental and investigational: Facet chemodenervation/ chemical facet neurolysis Laser facet denervation 	
Aetna (2012) <i>Clinical Policy</i> <i>Bulletin:</i> <i>Pulsed</i> <i>Radiofrequency</i> POLICY #: 0735 Effective Date: 08/21/2007 Last Review Date: 12/07/2012 Next Review Date: 09/23/2013		This policy is based upon references including RCTs, systematic reviews, retrospective Cohort study, case series study	 Aetna considers pulsed radiofrequency experimental and investigational for all indications, including those in the following list, because its effectiveness has not been established. Facet joint arthropathy Zygapophyseal joint pain. 	 Radiofrequency procedures have been reported to be associated with high number of complications compared with other ablative neurosurgical techniques. Furthermore, conventional (continuous) RF treatment occasionally results in worsening and even new onset of pain. The use of pulsed radiofrequency (PRF, also known as cold RF), a non- or minimally-neurodestructive and thus less painful technique, serves as an alternative to conventional RF therapy. Pulsed radiofrequency treatment, performed under fluoroscopic guidance, entails the use of pulsed time cycle that delivers short bursts of RF energy to nervous tissue.

Payer (year)	Lit search dates	Evidence base available [*]	Policy	Rationale/comments
Cigna (2012) Minimally Invasive Treatment of Back and Neck Pain POLICY #: 0139 Effective Date: 7/15/2012 Next Review Date: 7/15/2013	NR	This policy is based upon references including RCTs, systematic reviews, retrospective Cohort study, case series study, Meta- analysis and ASIPP practice guideline	 Cigna covers initial radiofrequency denervation of paravertebral facet joint nerves (also referred to as radiofrequency neurolysis, neurotomy, facet rhizotomy) (CPT codes 64633-64636) for the treatment of chronic back or neck pain as medically necessary when ALL of the following criteria are met: Pain is exacerbated by extension and rotation, or is associated with lumbar rigidity There is severe pain unresponsive to at least six months of conservative medical management. (e.g., pharmacological therapy, physical therapy, exercise) Facet joint origin of pain is suspected and medial branch block/injection of facet joint with local anesthetic results in elimination or marked decrease in intensity of pain Clinical findings and imaging studies suggest no other obvious cause of the pain (e.g., spinal stenosis, disc degeneration or herniation, infection, tumor, fracture) Cigna covers repeat radiofrequency denervation of paravertebral facet joint nerves at the same level for the treatment of chronic back or neck pain as medically necessary when BOTH of the following criteria are met: At least six months have elapsed since the previous radiofrequency ablation/neurolysis of paravertebral facet joint nerves More than 50% relief is obtained, with associated functional improvement, for at least ten weeks 	 Radiofrequency denervation of facet joints has been used to treat spinal pain presumed to be of facet origin. RFA was also been explored for the treatment of SI joint pain.

Payer (year)	Lit search dates	Evidence base available [*]	Policy	Rationale/comments
			 Cigna does not cover long-term or maintenance denervation of paravertebral facet joint nerves for any indication because it is considered not medically necessary. 	
			 Cigna does not cover ANY of the following ablative procedures for the treatment of back or neck pain because each is considered experimental, investigational or unproven (this list may not be all-inclusive); Pulsed radiofrequency (CPT code 64999) Cryoablation/cryoneurolysis/cryodenervation (CPT code 64999) Chemical ablation (e.g., alcohol, phenol, glycerol) (CPT codes 64622-64627) Laser ablation (CPT code 64999) Sacroiliac (SI) joint nerve ablation by any method (CPT code 64640) 	
Health Net (2012) <i>Facet Joint</i> <i>Denervation</i> POLICY #: NMP43 Effective Date: 10/2003 Last Review Date: 1/2012	PRF- Updated 1/2012 PRF (facet neurolysis)- Updated 7/2009	This policy is based upon references including RCTs, systematic reviews, cohort and retrospective studies	 Facet Joint Denervation (also referred to as neurolysis, lesioning, facet neurotomy, facet rhizotomy, or articular rhizolysis) by either injecting neurolytic substances (alcohol 50-100% or phenol) or utilizing radiofrequency thermoneurolysis (e.g. radiofrequency ablation, radiofrequency neurolysis, and/or radiofrequency thermoablation) or cryoneurolysis is medically necessary for treatment of patients with intractable chronic zygapophyseal cervical or lumbar joint pain with or without neurological compression symptoms when all of the following are met: Trial of facet joint injections using local anesthetic has been successful in relieving the pain or, at least, a > 50% reduction of pain; and Severe low back pain or cervical neck pain limiting activities of daily living has been present for at least 6 	 Note - Caution is recommended for RFA treatment in patients with diabetes mellitus and in those who have undergone prior back surgery at the pain site. Scientific Rationale – Update April 2008 (2007) American Society of Interventional Pain Physicians states: "Among the diagnostic interventions, the accuracy of facet joint nerve blocks is strong in the diagnosis of lumbar and cervical facet joint pain."

Payer (year)	Lit search dates	Evidence base available [*]	Policy	Rationale/comments
			 No prior spinal fusion surgery in the same area of the 	
			spine that is to undergo radiofrequency treatment; and	
			 Neuroradiologic studies are negative or fail to confirm 	
			disc herniation; and	
			 Patient has no significant narrowing of the vertebral 	
			canal or spinal instability requiring surgery; and	
			 Patient has tried and failed conservative treatments 	
			such as bed rest, back supports, physiotherapy,	
			correction of postural abnormality, as well as	
			pharmacotherapies (e.g. anti-inflammatory agents,	
			analgesics and muscle relaxants.	
			Relative or Absolute Contraindications to Radiofrequency	
			<u>Ablation</u> :	
			 Neurologic abnormalities; 	
			 Definitive clinical and/or imaging findings; 	
			 Proven specific causes of low back pain, including 	
			herniation, spondylolisthesis, spondylosis ankylopoetica,	
			spinal stenosis, discogenic or stenotic compression,	
			extensive multilevel spondylosis, clinical radiculopathy,	
			multiple sclerosis, coagulation disorders, pregnancy,	
			malignancy, infection, and trauma;	
			 Allergy to radiopaque contrast or local anesthetic; 	
			 More than one pain syndrome; 	
			 Lack of response to diagnostic nerve blocks; 	
			 Psychiatric disorders. 	
			Pulsed Radiofrequency Ablation	
			 Health Net, Inc. considers pulsed radiofrequency 	
			ablation investigational. The available evidence on the	
			effectiveness of pulsed radiofrequency in the treatment	
			of patients with various chronic pain syndromes is	
			largely based on retrospective, case series studies. Its	
			clinical value needs to be examined in well-designed,	

Payer (year)	Lit search dates	Evidence base available [*]	Policy	Rationale/comments
			randomized controlled trials with large sample size and long-term follow-up. Studies on pulsed radiofrequency ablation continue to be done.	

From pages 84- 92 of the evidence report

Assessment (year)	Search dates	Procedure(s) evaluated	Evidence base available	Recommendations	Class/Grade of Recommendation	Level of Evidence
American Pain	NR	Facet neurotomy,	RCTs	Criteria and grading system adapted from		
Society Clinical		radiofrequency		methods developed by the US Preventative	1	Poor
(2009)		denervation		Services Task Force [*]		
					1	Poor
Interventional				Diagnostic:		
Therapies, Surgery,				There is insufficient evidence to evaluate		
and				validity or utility of diagnostic selective nerve		
Interdisciplinary				root block, intra-articular facet joint block,		
Rehabilitation for				medial branch block, or sacroiliac joint block		
Low Back Pain An				as diagnostic procedures for low back pain		
Evidence-Based				with or without radiculopathy.		
Clinical Practice				 No reliable data exist on the diagnostic 		
Guideline From the				accuracy or clinical utility of diagnostic		
American Pain				facet joint, medial branch, or selective		
Society.				nerve root blocks. Correlation with		
				imaging findings is variable and difficult		
				to interpret in the absence of reliable		
				reference standards for identifying "true"		
				facet joint pain. Although positive		
				responses are less frequent with		
				controlled rather than uncontrolled facet		
				joint blocks, it is not possible to		
				determine whether this finding is due to		

Assessment (year)	Search dates	Procedure(s) evaluated	Evidence base available	Recommendations	Class/Grade of Recommendation	Level of Evidence
				fewer true- or false-positive cases. Some studies have evaluated the association between findings on invasive diagnostic tests and surgical outcomes, but no studies have investigated the effects of using facet joint, medial branch, or selective nerve root block to guide choice of therapy or how use of these tests affects subsequent patient outcomes, compared with selective therapy without using the invasive diagnostic test.		
				 Therapeutic: In patients with persistent nonradicular low back pain, there is insufficient evidence to adequately evaluate benefits of radiofrequency denervation. Trials of radiofrequency denervation reported inconsistent results between small numbers of higher quality trials and (in the case of radiofrequency denervation) technical or methodologic shortcomings making it difficult to reach conclusions about benefits. 		
National Institute for Health and Clinical Excellence/ National Collaborating Centre for Primary Care (2009) Low back pain: early management of persistent non-		Radiofrequency facet joint denervation	NR	 Evidence levels are based on the guidelines manual developed by the National Institute for Health and Clinical Excellence[†] <u>Do not refer people for any of the following</u> <u>procedures</u> The role of specific therapeutic interventions remains unclear: Case studies provide some evidence for the effectiveness of facet joint injections and medial branch blocks, but randomized 	NR	1+, 1-

Assessment (year)	Search dates	Procedure(s) evaluated	Evidence base available	Recommendations	Class/Grade of Recommendation	Level of Evidence
specific low back pain Full Guideline.				controlled trials give conflicting evidence.		
American College of Occupational	1966 – 2010	Radiofrequency neurotomy, neurotomy,	NR	Criteria and grading system are drafted by the EBPP of the Guideline Methodology		
and Environmental Medicine (2007/2011)		and facet rhizotomy		Committee for the American College of Occupational and Environmental Medicine [§]	Not recommended	С
Low back disorders Evaluation and management of common health problems and				Acute Low Back Pain, Subacute Low Back Pain, Radicular Pain Syndromes and Spinal Stenosis: Radiofrequency neurotomy, neurotomy, and facet rhizotomy are not recommended. The EBPP found at least intermediate evidence	Not recommended	C
functional recovery in workers.				that harms and costs exceed benefits based on limited evidence.	No recommendation	I
				Chronic Low Back Pain: Radiofrequency neurotomy, neurotomy, or facet rhizotomy for patients with chronic LBP confirmed with diagnostic blocks, but who do not have radiculopathy and who have failed conservative treatment – no		
				recommendation. The evidence is insufficient to recommend for or against routinely providing the intervention. Evidence that the intervention is effective is lacking, of poor quality, or conflicting and the		
				balance of benefits, harms, and costs cannot be determined.		

Assessment (year)	Search dates	Procedure(s) evaluated	Evidence base available	Recommendations	Class/Grade of Recommendation	Level of Evidence
American Society of Interventional Pain Physicians (2003/2009) Comprehensive	1966 – Dec 2008	Facet or zygapophysial joint blocks, medial joint blocks, radiofrequency neurotomy	NR	Grading recommendations adapted from Guyatt et al. (2006) ^{††} Quality of Evidence modified from the grading system developed by the U.S. Preventive Services Task Force ^{**} Diagnostic:	NR	l or II-I
evidence-based guidelines for interventional techniques in the management of				Low Back Pain: Diagnostic lumbar facet joint nerve blocks are recommended in patients suffering from somatic or non-radicular low back and lower extremity pain (avg. > 6 on scale of $0 - 10$),		
chronic spinal pain.				with duration of pain of at least 3 months. <u>Neck Pain:</u> Diagnostic cervical facet joint nerve blocks are recommended in patients suffering from somatic or non-radicular neck pain or headache and upper extremity pain, with	NR	l or II-l
				duration of pain (avg. > 6 on scale of $0 - 10$) of at least 3 months. <u>Thoracic Pain:</u> Facet or zygapophysial joint blocks are recommended in patients suffering from somatic or nonradicular upper back or mid back pain (avg. > 6 on scale of $0 - 10$) of at	NR 1C	- -1 to -3
				Therapeutic: Based on Guyatt et al.'s, (2006) criteria for cervical radiofrequency neurotomy and lumbar radiofrequency neurotomy, the recommendation is strong.		11-1 (U 11-3

Assessment (year)	Search dates	Procedure(s) evaluated	Evidence base available	Recommendations	Class/Grade of Recommendation	Level of Evidence
Colorado Division of Workers' Compensation (2011) Chronic pain disorder medical treatment guidelines.	2001 – 2010	Radiofrequency medial branch neurotomy/facet rhizotomy	NR	RF medial branch neurotomy is the procedure of choice over alcohol, phenol, or cryoablation. This treatment is indicated for patients with proven, significant, facetogenic pain. A minority of low back patients would be expected to qualify for this procedure. This procedure is not recommended for patients with multiple pain generators or involvement of more than 3 levels of medial branch nerves.	NR	NR
American College of Occupational and Environmental Medicine (2008)	1966 – 2008	Radiofrequency neurotomy, neurotomy, or facet rhizotomy	RCTs	Criteria and grading system are drafted by the EBPP of the Guideline Methodology Committee for the American College of Occupational and Environmental Medicine [§]	No	1
Chronic pain.				<u>Chronic Low Back Pain:</u> There is no recommendation for radiofrequency neurotomy, neurotomy, or facet rhizotomy for cervicogenic spinal conditions. The evidence is insufficient to recommend for or against routinely providing the intervention. The EBPP makes no recommendation. Evidence that the intervention is effective is lacking, of poor quality, or conflicting and the balance of benefits, harms, and costs cannot be determined.	recommendation Not recommended	с
				Radiofrequency neurotomy, neurotomy, or facet rhizotomy for lumbar spinal conditions is not recommended. The EBPP found at least moderate evidence that harms and costs exceed benefits based on limited evidence.		

Assessment (year)	Search dates	Procedure(s) evaluated	Evidence base available	Recommendations	Class/Grade of Recommendation	Level of Evidence
American College of Occupational and Environmental Medicine (2011)	NR	Use of radiofrequency neurotomy, neurotomy, and facet rhizotomy	NR	Criteria and grading system are drafted by the EBPP of the Guideline Methodology Committee for the American College of Occupational and Environmental Medicine [§]		
Cervical and thoracic spine disorders.				<u>Chronic Cervicothoracic Pain:</u> There is no recommendation for the use of radiofrequency neurotomy, neurotomy, and	No recommendation	1
				facet rhizotomy for chronic cervicothoracic pain confirmed with diagnostic blocks, but who do not have radiculopathy and who have failed conservative treatment. The evidence is insufficient to recommend for or against routinely providing the intervention. The EBPP makes no recommendation. Evidence that the intervention is effective is lacking, of poor quality, or conflicting and the balance of benefits, harms, and costs cannot be determined. <u>Cervicogenic Headache:</u> Radiofrequency neurotomy is moderately not recommended. Recommendation against routinely providing the intervention to eligible patients. The EBPP found at least intermediate evidence that the intervention is ineffective, or that harms or costs outweigh benefits.	Not recommended	В
Institute of Health Economics (2009/2011) <i>Guideline for the</i>	Jan 1996 – Dec 2010	Medial branch neurotomy	Systematic review (IHE) presenting consistent evidence to	Recommendation rating developed by the GDG ^{§§} <u>Chronic Low Back Pain:</u> Medial branch neurotomy is recommended	Do	NR
evidence-informed primary care			support the action.	for chronic low back pain.		

Assessment (year)	Search dates	Procedure(s) evaluated	Evidence base available	Recommendations	Class/Grade of Recommendation	Level of Evidence
management of low back pain.						
Work Loss Data Institute (2003/2008/2011) Neck and upper back (acute &	2003 – 2011	Facet joint radiofrequency neurotomy/facet rhizotomy	NR	Diagnostic facet blocks are recommended for patients with disorders of the neck and upper back, except those whom a surgical procedure is anticipated and in those who have had a previous fusion procedure at the planned injection level.	NR	NR
chronic).				Facet joint radiofrequency neurotomy/facet rhizotomy are currently under study and not specifically recommended.	NR	NR
Institute for Clinical Systems Improvement (ICSI) (2009/2011) Assessment and management of chronic pain.	Aug 2008 – Aug 2011	Percutaneous radiofrequency neurotomy	NR	Evidence grades determined by the ICSI *** Percutaneous radiofrequency neurotomy is recommended as a commonly used Level I therapeutic procedure for patients with neck and back pain generated by facet joints.	NR	1
Work Loss Data Institute (2003/2008/2011) Low Back-lumbar & thoracic (acute & chronic).	NR	Facet joint radiofrequency neurotomy/facet rhizotomy	NR	Facet joint radiofrequency neurotomy/facet rhizotomy are currently under study and not specifically recommended.	NR	NR
American Society of Regional Anesthesia and Pain Medicine	1944 – 2009	Chemical denervation, Radiofrequency ablation, radiofrequency ablation	NR	Chemical denervation (e.g., alcohol, phenol, or high concentration local anesthetics) is not recommended for routine care of patients with chronic non-cancer pain.	NR	NR

Assessment (year)	Search dates	Procedure(s) evaluated	Evidence base available	Recommendations	Class/Grade of Recommendation	Level of Evidence
(1997/2010)		(facet joint)			NR	NR
				Radiofrequency ablation:		
Practice guidelines				Conventional (e.g., 80°C) or thermal (e.g.,		
for chronic pain				67°C) radiofrequency ablation of the medial		
management. An				branch nerves to the facet joint is		
updated report by				recommended for low back (medial branch)		
the American				pain when previous diagnostic or therapeutic		
Society of				injections of the joint or medial branch nerve		
Anesthesiologists				have provided temporary relief.		
Task Force on						
Chronic Pain				Conventional radiofrequency ablation may be		
Management and				performed for neck pain.		
the American						
Society of Regional				Water-cooled radiofrequency ablation may		
Anesthesia and				be used for chronic sacroiliac joint pain.		
Pain Medicine.						

HEALTH TECHNOLOGY EVIDENCE IDENTIFICATION

Discussion Document: What are the key factors and health outcomes and what evidence is there?

Safety Outcomes	Safety Evidence		
Treatment related pain			
Treatment related sensibility changes			
Treatment related motor changes			
Adverse events			
Procedure related numbness			
Efficacy – Effectiveness Outcomes	Efficacy / Effectiveness Evidence		
Success (composite with pain, other measures)			
Back Pain			
Function			
Function success			
Leg pain			
Generalized pain			
Disability			
"accustomed" pain			
Headache pain			

Special Population / Considerations Outcomes	Special Population Evidence		
Sex			
Age			
Duration of pain			
Employment status			
Race			
Gender			
Back pain severity			
Leg pain severity			
Generalized pain severity			
Function level			
Cost	Cost Evidence		
Cost effectiveness			

Clinical Committee Evidence Votes

First Voting Question

The HTCC has reviewed and considered the technology assessment and information provided by the administrator, reports and/or testimony from an advisory group, and submissions or comments from the public. The committee has given greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable.

Is there sufficient evidence under some or all situations that the technology is:

	Unproven (no)	Equivalent (yes)	Less (yes)	More (yes)
Effective				
Safe				
Cost-effective				

Discussion

Based on the evidence vote, the committee may be ready to take a vote on coverage or further discussion may be warranted to understand the differences of opinions or to discuss the implications of the vote on a final coverage decision.

- Evidence is insufficient to make a conclusion about whether the health technology is safe, efficacious, and cost-effective;
- Evidence is sufficient to conclude that the health technology is unsafe, ineffectual, or not cost-effective
- Evidence is sufficient to conclude that the health technology is safe, efficacious, and cost-effective for all indicated conditions;
- Evidence is sufficient to conclude that the health technology is safe, efficacious, and cost-effective for some conditions or in some situations

A straw vote may be taken to determine whether, and in what area, further discussion is necessary.

Second Vote

Based on the evidence about the technologies' safety, efficacy, and cost-effectiveness, it is

____Not Covered ___ Covered Unconditionally ___ Covered Under Certain Conditions

Discussion Item

Is the determination consistent with identified Medicare decisions and expert guidelines, and if not, what evidence is relied upon?

Clinical Committee Findings and Decisions

Next Step: Cover or No Cover

If not covered, or covered unconditionally, the Chair will instruct staff to write a proposed findings and decision document for review and final adoption at the following meeting.

Next Step: Cover with Conditions

If covered with conditions, the Committee will continue discussion.

1) Does the committee have enough information to identify conditions or criteria?

- Refer to evidence identification document and discussion.
- Chair will facilitate discussion, and if enough members agree, conditions and/or criteria will be identified and listed.
- Chair will instruct staff to write a proposed findings and decision document for review and final adoption at next meeting.

2) If not enough or appropriate information, then Chair will facilitate a discussion on the following:

- What are the known conditions/criteria and evidence state
- What issues need to be addressed and evidence state

The chair will delegate investigation and return to group based on information and issues identified. Information known but not available or assembled can be gathered by staff; additional clinical questions may need further research by evidence center or may need ad hoc advisory group; information on agency utilization, similar coverage decisions may need agency or other health plan input; information on current practice in community or beneficiary preference may need further public input. Delegation should include specific instructions on the task, assignment or issue; include a time frame; provide direction on membership or input if a group is to be convened.

Efficacy Considerations:

- What is the evidence that use of the technology results in more beneficial, important health outcomes? Consider:
 - Direct outcome or surrogate measure
 - Short term or long term effect
 - Magnitude of effect
 - o Impact on pain, functional restoration, quality of life
 - Disease management
- What is the evidence confirming that use of the technology results in a more beneficial outcome, compared to no treatment or placebo treatment?
- What is the evidence confirming that use of the technology results in a more beneficial outcome, compared to alternative treatment?
- What is the evidence of the magnitude of the benefit or the incremental value
- Does the scientific evidence confirm that use of the technology can effectively replace other technologies or is this additive?
- For diagnostic tests, what is the evidence of a diagnostic tests' accuracy
 - Does the use of the technology more accurately identify both those with the condition being evaluated and those without the condition being evaluated?
- Does the use of the technology result in better sensitivity and better specificity?

- Is there a tradeoff in sensitivity and specificity that on balance the diagnostic technology is thought to be more accurate than current diagnostic testing?
- Does use of the test change treatment choices

<u>Safety</u>

- What is the evidence of the effect of using the technology on significant morbidity?
 - Frequent adverse effect on health, but unlikely to result in lasting harm or be lifethreatening, or;
 - Adverse effect on health that can result in lasting harm or can be life-threatening.
- Other morbidity concerns
- Short term or direct complication versus long term complications
- What is the evidence of using the technology on mortality does it result in fewer adverse non-fatal outcomes?

Cost Impact

• Do the cost analyses show that use of the new technology will result in costs that are greater, equivalent or lower than management without use of the technology?

<u>Overall</u>

- What is the evidence about alternatives and comparisons to the alternatives
- Does scientific evidence confirm that use of the technology results in better health outcomes than management without use of the technology?